VIGL Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-03-01 | Verni Christopher | officer: General Counsel | 85,000 | A-Award | A | 85,000 | 11.87 | 1,008,950.00 |
| 2023-03-01 | Booth Bruce | director | 9,713 | A-Award | A | 9,713 | 11.87 | 115,293.31 |
| 2023-03-01 | Bruhn Suzanne Louise | director | 6,235 | A-Award | A | 6,235 | 11.87 | 74,009.45 |
| 2023-03-01 | Magovcevic-Liebisch Ivana | director, officer: President and CEO | 370,000 | A-Award | A | 370,000 | 11.87 | 4,391,900.00 |
| 2023-03-01 | Ziolkowski Jennifer Lynn | officer: Chief Financial Officer | 135,000 | A-Award | A | 135,000 | 11.87 | 1,602,450.00 |
| 2023-03-01 | Blanchard Cheryl R | director | 6,432 | A-Award | A | 6,432 | 11.87 | 76,347.84 |
| 2023-03-01 | Thackaberry Evan | officer: SVP, Head of Early Development | 65,000 | A-Award | A | 65,000 | 11.87 | 771,550.00 |
| 2023-02-27 | Gray David L. F. | officer: Chief Science Officer | 267,000 | A-Award | A | 267,000 | 12.09 | 3,228,030.00 |
| 2022-11-18 | Papapetropoulos Spyros | officer: Chief Medical Officer | 149,604 | M-Exempt | D | 300 | 1.89 | 567.00 |
| 2022-11-18 | Papapetropoulos Spyros | officer: Chief Medical Officer | 4,000 | S-Sale | D | 300 | 14.00 | 4,200.00 |
| 2022-11-18 | Papapetropoulos Spyros | officer: Chief Medical Officer | 4,300 | M-Exempt | A | 300 | 1.89 | 567.00 |
| 2022-07-27 | Bruhn Suzanne Louise | director | 24,310 | A-Award | A | 24,310 | 6.93 | 168,468.30 |
| 2022-06-09 | Thistle Mary | director | 12,155 | A-Award | A | 12,155 | 3.10 | 37,680.50 |
| 2022-06-09 | Blanchard Cheryl R | director | 12,155 | A-Award | A | 12,155 | 3.10 | 37,680.50 |
| 2022-06-09 | Vitorovic Stefan | director | 12,155 | A-Award | A | 12,155 | 3.10 | 37,680.50 |
| 2022-06-09 | Booth Bruce | director | 12,155 | A-Award | A | 12,155 | 3.10 | 37,680.50 |
| 2022-06-09 | Koenig Gerhard | director | 12,155 | A-Award | A | 12,155 | 3.10 | 37,680.50 |
| 2022-05-17 | Thorp Clay | director | 1,556,030 | P-Purchase | A | 14,893 | 2.97 | 44,189.02 |
| 2022-05-16 | Thorp Clay | director | 1,541,137 | P-Purchase | A | 21,802 | 2.76 | 60,221.48 |
| 2022-05-05 | Thackaberry Evan | officer: SVP, Head of Early Development | 1,500 | P-Purchase | A | 1,500 | 4.00 | 6,000.00 |
| 2022-05-03 | Papapetropoulos Spyros | officer: Chief Medical Officer | 4,000 | P-Purchase | A | 4,000 | 3.40 | 13,591.20 |
| 2022-05-03 | Ziolkowski Jennifer Lynn | officer: Chief Financial Officer | 4,000 | P-Purchase | A | 4,000 | 3.77 | 15,097.60 |
| 2022-05-03 | Magovcevic-Liebisch Ivana | director, officer: President and CEO | 203,687 | P-Purchase | A | 1,000 | 3.94 | 3,940.20 |
| 2022-05-03 | Verni Christopher | officer: General Counsel | 4,000 | P-Purchase | A | 4,000 | 3.77 | 15,074.40 |
| 2022-05-02 | Magovcevic-Liebisch Ivana | director, officer: President and CEO | 202,687 | P-Purchase | A | 4,000 | 3.61 | 14,438.80 |
| 2022-04-19 | Verni Christopher | officer: General Counsel | 150,000 | A-Award | A | 150,000 | 7.06 | 1,059,000.00 |
| 2022-04-18 | Thistle Mary | director | 24,309 | A-Award | A | 24,309 | 6.80 | 165,301.20 |
| 2022-03-28 | Thorp Clay | director | 3,000 | P-Purchase | A | 3,000 | 7.20 | 21,604.20 |
| 2022-03-01 | Ziolkowski Jennifer Lynn | officer: Chief Financial Officer | 110,000 | A-Award | A | 110,000 | 16.13 | 1,774,300.00 |
| 2022-03-01 | Thackaberry Evan | officer: SVP, Head of Early Development | 45,000 | A-Award | A | 45,000 | 16.13 | 725,850.00 |
| 2022-03-01 | Papapetropoulos Spyridon | officer: Chief Medical Officer | 75,500 | A-Award | A | 75,500 | 16.13 | 1,217,815.00 |
| 2022-03-01 | Blanchard Cheryl R | director | 5,017 | A-Award | A | 5,017 | 16.13 | 80,924.21 |
| 2022-03-01 | Booth Bruce | director | 7,577 | A-Award | A | 7,577 | 16.13 | 122,217.01 |
| 2022-03-01 | Magovcevic-Liebisch Ivana | director, officer: President and CEO | 282,000 | A-Award | A | 282,000 | 16.13 | 4,548,660.00 |
| 2022-03-01 | Koenig Gerhard | director | 4,351 | A-Award | A | 4,351 | 16.13 | 70,181.63 |
| 2022-01-11 | Cormorant Asset Management, LP | other: Former 10% Owner | 0 | C-Conversion | D | 616,786 | 0.00 | 0.00 |
| 2022-01-11 | Cormorant Asset Management, LP | other: Former 10% Owner | 616,786 | C-Conversion | A | 616,786 | 0.00 | 0.00 |
| 2022-01-11 | AMGEN INC | 10 percent owner | 0 | C-Conversion | D | 3,206,281 | 0.00 | 0.00 |
| 2022-01-11 | AMGEN INC | 10 percent owner | 3,206,281 | C-Conversion | A | 3,206,281 | 0.00 | 0.00 |
| 2022-01-11 | Vida Ventures GP III, L.L.C. | 10 percent owner | 0 | C-Conversion | D | 21,310 | 0.00 | 0.00 |
| 2022-01-11 | Vida Ventures GP III, L.L.C. | 10 percent owner | 11,536 | P-Purchase | A | 3,852 | 14.00 | 53,928.00 |
| 2022-01-11 | Vida Ventures GP III, L.L.C. | 10 percent owner | 5,004,393 | P-Purchase | A | 1,671,148 | 14.00 | 23,396,072.00 |
| 2022-01-11 | Vida Ventures GP III, L.L.C. | 10 percent owner | 7,684 | C-Conversion | A | 7,684 | 0.00 | 0.00 |
| 2022-01-11 | Vida Ventures GP III, L.L.C. | 10 percent owner | 3,333,245 | C-Conversion | A | 3,333,245 | 0.00 | 0.00 |
| 2022-01-11 | Thorp Clay | director | 0 | C-Conversion | D | 926,506 | 0.00 | 0.00 |
| 2022-01-11 | Thorp Clay | director | 0 | C-Conversion | D | 926,506 | 0.00 | 0.00 |
| 2022-01-11 | Thorp Clay | director | 1,519,335 | P-Purchase | A | 265,000 | 14.00 | 3,710,000.00 |
| 2022-01-11 | Thorp Clay | director | 1,254,335 | C-Conversion | A | 1,254,335 | 0.00 | 0.00 |
| 2022-01-11 | Atlas Venture Fund XII, L.P. | 10 percent owner | 0 | C-Conversion | D | 2,850,789 | 0.00 | 0.00 |
| 2022-01-11 | Atlas Venture Fund XII, L.P. | 10 percent owner | 0 | C-Conversion | D | 2,850,789 | 0.00 | 0.00 |
| 2022-01-11 | Atlas Venture Fund XII, L.P. | 10 percent owner | 4,808,896 | P-Purchase | A | 535,000 | 14.00 | 7,490,000.00 |
| 2022-01-11 | Atlas Venture Fund XII, L.P. | 10 percent owner | 1,027,978 | C-Conversion | A | 1,027,978 | 0.00 | 0.00 |
| 2022-01-11 | Atlas Venture Fund XII, L.P. | 10 percent owner | 4,273,896 | C-Conversion | A | 2,831,520 | 0.00 | 0.00 |
| 2022-01-11 | Vitorovic Stefan | director | 0 | C-Conversion | D | 21,310 | 0.00 | 0.00 |
| 2022-01-11 | Vitorovic Stefan | director | 11,536 | P-Purchase | A | 3,852 | 14.00 | 53,928.00 |
| 2022-01-11 | Vitorovic Stefan | director | 5,004,393 | P-Purchase | A | 1,671,148 | 14.00 | 23,396,072.00 |
| 2022-01-11 | Vitorovic Stefan | director | 7,684 | C-Conversion | A | 7,684 | 0.00 | 0.00 |
| 2022-01-11 | Vitorovic Stefan | director | 3,333,245 | C-Conversion | A | 3,333,245 | 0.00 | 0.00 |
| 2022-01-11 | Booth Bruce | director | 0 | C-Conversion | D | 2,850,789 | 0.00 | 0.00 |
| 2022-01-11 | Booth Bruce | director | 0 | C-Conversion | D | 2,850,789 | 0.00 | 0.00 |
| 2022-01-11 | Booth Bruce | director | 4,808,896 | P-Purchase | A | 535,000 | 14.00 | 7,490,000.00 |
| 2022-01-11 | Booth Bruce | director | 1,027,978 | C-Conversion | A | 1,027,978 | 0.00 | 0.00 |
| 2022-01-11 | Booth Bruce | director | 4,273,896 | C-Conversion | A | 2,831,520 | 0.00 | 0.00 |
| 2022-01-11 | Northpond Ventures GP, LLC | 10 percent owner | 0 | C-Conversion | D | 1,027,978 | 0.00 | 0.00 |
| 2022-01-11 | Northpond Ventures GP, LLC | 10 percent owner | 0 | C-Conversion | D | 1,027,978 | 0.00 | 0.00 |
| 2022-01-11 | Northpond Ventures GP, LLC | 10 percent owner | 1,382,978 | P-Purchase | A | 355,000 | 14.00 | 4,970,000.00 |
| 2022-01-11 | Northpond Ventures GP, LLC | 10 percent owner | 1,027,978 | C-Conversion | A | 1,027,978 | 0.00 | 0.00 |
| 2022-01-11 | Northpond Ventures GP, LLC | 10 percent owner | 2,831,520 | C-Conversion | A | 2,831,520 | 0.00 | 0.00 |
| 2022-01-11 | Alexandria Venture Investments, LLC | 10 percent owner | 0 | C-Conversion | D | 142,539 | 0.00 | 0.00 |
| 2022-01-11 | Alexandria Venture Investments, LLC | 10 percent owner | 0 | C-Conversion | D | 142,539 | 0.00 | 0.00 |
| 2022-01-11 | Alexandria Venture Investments, LLC | 10 percent owner | 192,973 | C-Conversion | A | 192,973 | 0.00 | 0.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.